Phibro Animal Health Corporation · NASDAQ:PAHC

Phibro Animal Health — Q4 FY2023 Earnings Presentation

15 slides from Phibro Animal Health's earnings presentation, Aug 31, 2023

  1. Slide 1: Phibro Animal Health Corporation Webcast and Conference Call

    Phibro Animal Health Corporation DRAF Webcast and Conference Call August 31, 2023 Financial Results U.S. toll-free +1-888-330-2022 Fourth Quarter and Year Ended June 30, 2023 International toll +1-365-977-0051 Conference ID: 3927884

  2. Slide 2: Important Information

    Important Information Cautionary Statement Regarding Forward-Looking Statements This communication contains forward-looking statements that are subject to risks and uncertainties, including with respect to future debt and leverage levels. All statements other than statements of historical or current

  3. Slide 3: Key Themes: Fourth Quarter & Fiscal Year 2023

    Key Themes Fourth Quarter & Fiscal Year 2023 Strong growth Successfully Projecting continued in our Animal Health fueled manufacturing growth in product portfolio and innovation fiscal year 2024 Year-over-year net sales and Phibro remains committed to its We are providing fiscal year adjusted EBITDA

  4. Slide 4: Financial Performance - Consolidated, Fourth Quarter

    Financial Performance - Consolidated Fourth Quarter, Year-on-Year comparison $ in millions, except per share data YOY  Net Sales – a decrease of $0.2 million, or less than 1%, driven by declining sales in Mineral Nutrition Q4 %∆ offset by growth in Animal Health and Performance Products Consolidate

  5. Slide 5: Financial Performance - Consolidated, Fiscal Year 2023

    Financial Performance - Consolidated Fiscal Year 2023, Year-on-Year comparison $ in millions, except per share data YOY  Net Sales – an increase of $35.6 million, or 4%, driven by strong growth in Animal Health offset partially by sales FY 2023 %∆ declines in both Mineral Nutrition and Performance

  6. Slide 6: Financial Performance – Animal Health, Fourth Quarter

    Financial Performance – Animal Health Fourth Quarter, Year-on-Year comparison $ in millions YOY  Net Sales – an increase of $10.2 million, or 6% Q4 %∆  MFAs and other – an increase of $2.4 million, or 2%  Driven by increased demand for processing aids used in the Animal Health ethanol fermentatio

  7. Slide 7: Financial Performance – Animal Health, Fiscal Year 2023

    Financial Performance – Animal Health Fiscal Year 2023, Year-on-Year comparison $ in millions YOY  Net Sales – an increase of $52.8 million, or 9% FY 2023 %∆  MFAs and other – an increase of $25.8 million, or 7% Animal Health  Driven by increased demand for MFAs, particularly in the US and Latin

  8. Slide 8: Financial Performance – Other Segments, Fourth Quarter

    Financial Performance – Other Segments Fourth Quarter, Year-on-Year comparison $ in millions YOY Q4 %∆  Mineral Nutrition Mineral Nutrition  Net Sales decreased $10.9 million, or 16%, driven by a decrease in demand for trace minerals, partially offset by higher average selling Net Sales $ 58.4 (16

  9. Slide 9: Financial Performance – Other Segments, Fiscal Year 2023

    Financial Performance – Other Segments Fiscal Year 2023, Year-on-Year comparison $ in millions YOY FY 2023 %∆  Mineral Nutrition Mineral Nutrition  Net Sales decreased $16.9 million, or 6%, driven by a decrease in demand for trace minerals, partially offset by higher average selling Net Sales $ 24

  10. Slide 10: Key Capitalization Metrics

    Key Capitalization Metrics Fiscal Year 2023 Highlights $m Trailing Quarter Ending -$24 million of trailing 12-month free cash flow; 12-Months 06.30.23 03.31.23 12.31.22 09.30.22 Free Cash Flow operating cash flow of $13 million, less capital Operating Cash Flow $ 13 $ 20 $ (11) 6 $ (8) (2) $ (10) (1

  11. Slide 11: Fiscal Year 2024 Guidance

    Fiscal Year 2024 Guidance August 31, 2023

  12. Slide 12: Financial Guidance, highlights

    Financial Guidance, highlights Fiscal Year 2024 Projected Sales & Adjusted EBITDA, consolidated $ in millions On a consolidated basis, we are projecting another year of profitable growth: $1,050  Projected consolidated growth is driven by Animal Health, while Mineral Nutrition & Performance Product

  13. Slide 13: Financial Guidance, Fiscal Year 2024

    Financial Guidance Fiscal Year 2024 $ in millions, except earnings per share (EPS) data At guidance mid-points, we are projecting:  Net Sales & Adjusted EBITDA, 5% growth FY 2023 FY 2024  Fueled by 8% and 9% growth in Animal Health net sales and Full Year Guidance Adjusted EBITDA, respectively, Ac

  14. Slide 14: Q&A

    1 August 31 2023 HEALTHY ANIMALS. HEALTHY FOOD. HEALTHY WORLD.

  15. Slide 15: © 2023 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy

    © 2023 Phibro Animal Health Corporation, Teaneck, NJ 07666 Phibro; Phibro logo design; Healthy Animals. Healthy Food. Healthy World.; and any other Phibro brand or brands shown herein are trademarks owned by or licensed to Phibro Animal Health Corporation or its affiliates. Any other trademark that

Phibro Animal Health — Q4 FY2023 Earnings Presentation on 6ix